Farmaprojects | Polpharma Group

While RNA therapies have existed since 1998, the market remained small for nearly two decades. But since 2016, we've seen a surge in activity. siRNAs, ASOs, and mRNAs account for 80% of the RNA therapeutics pipeline. 1 out of 3 therapies are estimated to treat cardiometabolic disorders. 🟨 Farmaprojects | Polpharma Group is at the forefront of the market. We are working to develop complex RNA-based generics. Discover more: https://lnkd.in/d-fMY7id #RNATherapeutics #R&D #B2BPharma #Portfolio #Farmaprojects 

How do we connect potential ideas to develop new generics with real-world necessities? 💡 Innovation culture systematization At Farmaprojects | Polpharma Group we encourage all team members to contribute by proposing new ideas and molecules using an internal platform. Within 24 hours the portfolio team does a funnel analysis and evaluates which ones hold great potential. Regardless of the department, everyone can create an impact. As a result of our innovation and collaboration culture, in 2024 we have added 6 molecules to the pipeline. 🟨 As the hub B2B of the Polpharma Group, the agility of our team meets the manufacturing capabilities of Poland's biggest laboratory. #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #Portfolio

💬 "A good leader must not only provide vision but also ensure that the team has the resources to operate." - Bernardo Reiner, General Manager at Farmaprojects | Polpharma Group. In B2B Pharma, ideation to commercialization can take between 5 and 8 years. How to be a balanced leader in this long-term game? ✅ Provide an accurate vision of your strategic bets at the portfolio level. ✅ Form a dynamic team to offer the best service to your clients. Read more insights about Bernardo's leadership in the Balanced Leaders interview by Talengo: https://lnkd.in/d7spBKck #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #PharmaceuticalIndustry

✅ We build on our achievements. Farmaprojects | Polpharma Group ended 2024 with accomplishments that serve as a strong foundation to start 2025. After an intense January, we are ready to make 2025 an even more successful year. We are a faster, more agile company with new processes in place, an expanding team, and a defined OneTeam culture. This year has been about saying YES. Yes to Agility. Yes to Growth. Yes to You. 🟨 We are eager for more in 2025. We are ready to shape the future of B2B in the pharmaceutical industry, together with you. #YesYouHealth #Farmaprojects #Polpharma #B2BPharma

We are flying to New York City! The Farmaprojects team will attend DCAT Week 2025 from March 17th to 20th. It’s the perfect opportunity to connect and discuss how Farmaprojects | Polpharma Group can support your pharmaceutical projects. We are seeking potential partners for our US portfolio which includes oligonucleotides, respiratory, and ophthalmics. If you are attending DCAT Week, you can connect with Bernardo Reiner and Roberto Asensio and find potential collaboration opportunities. 📍 New York City | Fifty Sonesta, NY 155 East 50th St. #Cornell Penthouse PH2-22nd floor 🗓️ March 17-20 We look forward to connecting with our esteemed partners and friends during this industry event. #DCATWeek #Farmaprojects #PortfolioStrategy #PartnershipOpportunities

💊 Yes to value creation in generics! Nanoform We believe that defining new ways of partnering paves the way for new opportunities in the B2B industry. Together with our colleagues from Polpharma, our team enjoyed the opportunity to visit our partner Nanoform in Helsinki. From Nanoform’s unique, state-of-the-art facilities to inspiring conversations about current and future projects, the visit was a great success and showcases Farmaprojects | Polpharma Group commitment to investing in added value and innovative technologies. A big thank you to Nanoform's talented team for providing a welcoming experience. Until next time in Helsinki!

Are you better off than you were 6 months ago? 📈 At all levels, this question is the principal KPI at Farmaprojects | Polpharma Group: processes, structure, and employee well-being. Andrea Castañar Esteban has interviewed Bernardo Reiner, our General Manager, at Disruptores Digitales, a podcast by InboundCycle | Agencia Inbound. Learn more about his vision and how he has led Farmaprojects' transformation to become the agile B2B hub of the Polpharma Group. 🎧 Listen to the episode: https://lnkd.in/dXFmBf8C #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #PharmaceuticalIndustry

Glaucoma patients who need long-term treatments often experience cumulative side effects from preservatives. 👁️ Preservative-free multidose solutions are safer for extended use. Farmaprojects | Polpharma Group Ophthalmics Portfolio includes several generics in this format for ophthalmologic condition treatments. https://lnkd.in/ds2kuV93 #Glaucoma #EyeHealth #Ophthalmology #Portfolio

Welcome to the team, Clara Elias!  Our vision is to become the best B2B company for our partners, customers, and employees. And yes, part of this vision is also providing the best working experience for you. As a key person in this journey, you’ll help grow our teams and bring in the best talent, contributing to our goals. Thank you Clara. 🚀 Always remember: Yes You Health! 🚀

🟨 Farma Academy is here! At Farmaprojects | Polpharma Group, we've launched a new platform to share knowledge and innovation across our organization. Farma Academy is a space to better understand new products and solutions, market needs, and trends. It empowers every team member to contribute their expertise and ideas, adding value not only to our company but to the entire healthcare chain. We have kicked off with a session about oligonucleotides. The first of many about diverse topics! Yes to empowerment. Yes to innovation. Yes to make things happen. Yes You Health.